Clinical Trial

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-28
Trial Details
NCT Number NCT07230106
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Prostate Cancer
Enrollment 218 participants
Start Date 2025-12-08
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-03